Chimeric antigen receptor (CAR) T-cell therapy has transformed the cancer treatment landscape, utilizing ex vivo modified autologous T cells to treat relapsed or refractory B-cell leukemias and lymphomas. However, the therapy’s broader impact has been limited, in part, by a complicated, lengthy, and expensive production process. Accordingly, as CAR T-cell therapies are further advanced to treat other cancers, continual innovation in cell manufacturing will be critical to their successful clinical implementation. In this Account, we describe our research efforts using biomaterials to improve the three fundamental steps in CAR T-cell manufacturing: (1) isolation, (2) activation, and (3) genetic modification.

中文翻译：

---

嵌合抗原受体T细胞过程开发中的生物材料。

嵌合抗原受体（CAR）T细胞疗法利用离体修饰的自体T细胞治疗复发性或难治性B细胞白血病和淋巴瘤，已经改变了癌症的治疗方法。但是，该疗法的广泛影响部分受到复杂，冗长且昂贵的生产过程的限制。因此，随着CAR T细胞疗法的进一步发展以治疗其他癌症，细胞制造领域的不断创新对于其成功的临床实施至关重要。在本报告中，我们描述了我们使用生物材料改善CAR T细胞制造的三个基本步骤的研究工作：（1）分离，（2）激活和（3）基因修饰。